S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Advaxis Provides 2014 Year-End Review and 2015 Outlook (2015/1/12)|
|ADXS Shareholder Alert: The Law Firm of Wohl & Fruchter LLP Announces Investigation of Advaxis, Inc. (2015/1/21)|
|Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer (2015/1/7)|
|Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers (2014/12/15)|
|Advaxis, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing (2015/1/28)|
|Federman & Sherwood Investigates Advaxis, Inc. For Possible Violations of Federal Securities Laws (2015/1/22)|
|ADXS SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Advaxis, Inc. (2015/1/22)|
|Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer (2014/12/8)|
|Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2 (2015/1/5)|
|Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria (2015/1/28)|
Click above to view more mutual fund data and stats for adx - ADX Energy Ltd.